Interview of Emmanuel Chartier-Kastler on UroActive for Stress Urinary Incontinence
Emmanuel Chartier-Kastler, MD, PhD, discusses UroActiveⓇ, an implantable device for women with stress urinary incontinence (SUI).
Read More
Emmanuel Chartier-Kastler, MD, PhD, FEBU
Emmanuel Chartier-Kastler, MD, PhD, FEBU, is Head of the Department of Urology at the Pitié-Salpêtrière Academic Hospital at Sorbonne University in Paris, France. Previously at this institution, he was a fellow and assistant professor between 1992 and 1998 in the department of urology.
Dr. Chartier-Kastler received his MD from Pierre and Marie Curie, University Paris 6, in Paris, France. He has held the role of professor of urology at the same university since September 2001.
Dr. Chartier-Kastler is an active member of the board of the French Association of Urology (AFU), past general secretary (2004-2007) and past chairman of the scientific committee, past member of the AFU Neurourology Committee, and an active member of the French speaking group of Neurourology (GENULF, past secretary general). He participates annually in ESU courses and EAU educational activities.
Past involvement includes participating in the French consensus conference regarding urinary nosocomial infections (2004), serving on the committee for conservative treatment in the neuropathic area during the International Consultation on Incontinence (ICI) from 1998 to 2006, and acting as committee co-chair for the SIU-ICUD consultation on spinal cord injury. As a neurologist, he prepared the final report of the 2006 French Congress of Urology in 2006. He has been a member of the organizing committee of major international meetings taking place in Paris (ICS-IUGA 2004 and 100th SIU 2007 Congress) as well as national meetings (French Congress Organizer 2005, 2006 and 2007). He also co-chaired the 2015 International UroGynecological Association Congress.
Prof. Chartier-Kastler has published more than 330 peer-reviewed articles and book chapters. Ongoing projects concern evaluation of new drugs for botulinum toxin for overactive bladder and BPH, interstitial cystitis evaluation, and animal models for study of neuromodulation mechanisms of action.
Talks by Emmanuel Chartier-Kastler, MD, PhD, FEBU